Tuesday, April 02, 2019 7:21:03 AM
The ASCENIV(TM) pivotal Phase III clinical study followed FDA guidance for treatment of patients with PI. The study enrolled fifty-nine patients with PI at nine sites across the U.S. in which study patients received regular infusions of ASCENIV(TM) over the course of one year. The trial's primary endpoint evaluated the rate of Serious Bacterial Infections ("SBI") in patients treated with ASCENIV(TM). Secondary endpoints included time to first SBI and to first serious infection, days on antibiotics, days off school or work due to infections, all confirmed infections of any kind, and hospitalizations due to infection. There were zero SBIs during the 12-month study period. The manuscript and data set describing the results are published by Dr. Richard Wasserman, et al in the Journal of Clinical Immunology (2016) Volume 36: 590-599. The approved labeling will include a boxed warning about potential thrombosis and renal dysfunction or failure, as well as the most common adverse events observed in the pivotal study, which were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.
"We are excited about this significant achievement in receiving FDA approval for ASCENIV(TM) a novel, patented IVIG product that we feel is a necessary addition to existing available therapies for patients who suffer from PI. We hope availability of ASCENIV(TM) will help ameliorate a portion of the current shortages facing U.S. IVIG supply," stated Adam Grossman, President and CEO of ADMA Biologics. "There are approximately 250,000 PI patients diagnosed and living in the U.S., and we believe there is an opportunity to treat meaningful segments of this patient population with ASCENIV(TM). As previously disclosed, ASCENIV(TM) is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested using our proprietary microneutralization assay. Going forward, we believe this FDA approval better positions ADMA to further its mission to evaluate ASCENIV(TM) in immune-compromised patients infected with or at-risk for Respiratory Syncytial Virus ("RSV") infection. We look forward to working with the FDA and the immunology and infectious disease community on developing a clinical investigation to evaluate use of ASCENIV(TM) in this patient population in the near future."
New York Yankees and Duke Basketball
Recent ADMA News
- ADMA Biologics Set to Join S&P SmallCap 600 Index • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 01:00:24 AM
- ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 01:00:31 AM
- Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 09/06/2024 10:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/31/2024 01:05:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/31/2024 01:02:08 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/31/2024 01:00:10 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 01:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 01:22:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 01:00:24 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/27/2024 01:28:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 01:05:31 PM
- ADMA Biologics Announces Partial Paydown of Revolving Credit Facility • GlobeNewswire Inc. • 08/14/2024 12:59:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:10:34 PM
- ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/27/2024 01:10:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/27/2024 01:05:33 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/27/2024 01:00:10 AM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM